IL-12 Deaths: Explanation and a Puzzle
By J. Cohen. 1995
Researchers investigating toxic reactions that killed two patients in a trial of interleukin-12 earlier this year have reached a surprising conclusion: The drug is highly toxic if it is given in multiple high doses, but those effects can be avoided if the multiple doses are preceded by a single dose followed by a rest period. The initial dose apparently imprints a memory on the immune system, but the mechanism is unclear.
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- J. Becker
- M. Jakóbisiak
- Witold Lasek
- R. Zagożdżon
- D. Schrama
- R. Reisfeld
Citations in the corpus
- Antibody targeted drugs as cancer therapeutics (2006, background): “As a result, systemic administration of cytokine doses that mimic this physiological mode of action are frequently accompanied by severe side effect”
- Interleukin 12: still a promising candidate for tumor immunotherapy? (2014, background): “Finally, after several months of suspension, clinical trials were resumed in several centers [120].”